ART Announces CE Mark Clearance for its Pure Bioresorbable Scaffold

Paris, May 18, 2015 – Privately-held company Arterial Remodeling Technologies (“ART”) today announces CE Mark clearance for its next generation drug free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre- clinical research, including up to three-years of follow-up, and supportive clinical results from leading coronary angioplasty centres such as the Hôpital Européen Georges Pompidou in Paris and investigators such as Dr Jean Fajadet at the Clinique Pasteur in Toulouse.


ART-News 150518